Changes of serum AGR2 of advanced non-small cell lung cancer before and after chemotherapy and its clinical significance
QIN Fang
WANG Hongwu
ZHOU Yunzhi
HE Xiaoyun
ZHANG Nan
Abstract：Objective To investigate the changes of serum anterior gradient-2 ( AGR2) in patients with advanced non-small cell lung cancer ( NSCLC) before and after chemotherapy and the relationship of it with prognosis. Methods From June 2013 to Sep-tember 2015, 35 patients with NSCLC were treated with gemcitabine and cisplatin regimen ( treatment group) . Meanwhile, 20 healthy volunteers were enrolled as control group. The level of serum AGR2 was detected by ELISA in treatment group before and after chemo-therapy and control group. The relationship of serum AGR2 with prognosis and clinical pathologic features was analyzed. Results The level of serum AGR2 before chemotherapy in treatment group was (15. 63±5. 20) ng/ml, higher than (3. 65±1. 38) ng/ml in control group (P<0. 01). Serum level of AGR2 after chemotherapy was (8. 56±2. 66) ng/ml, significantly lower than the level before chemo-therapy in NSCLC patients ( P<0. 01) . The serum levels of AGR2 in NSCLC patients before and after chemotherapy were closely relat-ed to tumor size and clinical stages ( P<0. 05) . Cox proportional hazards regression models showed that the level of serum AGR2 before chemotherapy was an independent factor of influencing the survival time. Conclusion The level of serum AGR2 may have potential clinical value to assess the therapeutic efficacy of chemotherapy and prognosis in patients of NSCLC.
Keywords：Non-small cell lung cancerAnterior gradient-2PrognosisELISA methodChemotherapy
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1015-1018 )